Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 532 participants.
Also called NCT02252965
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 532 participants
- Registry
-
NCT02252965
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT02252965. Randomized; no masking; primary purpose treatment. Start 2014-12 (registry gives no type); primary completion 2015-11 (actual). Results posted on 2017-01-24.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes
- Acronym
- CONSENT
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Metformin IR
- Intervention (Drug)
- Metformin XR
- Lead sponsor
- Merck KGaA, Darmstadt, Germany
Record details
- Record id
cardio:ct-nct02252965- Content hash
bd55ec67d179e9319e70e67a2da8e06ef11e788b8da6b67815b5344010390ae1